Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune's Vectra Testing Business to LabcorpGlobeNewsWire • 05/03/21
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor DayGlobeNewsWire • 05/03/21
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and TreatmentGlobeNewsWire • 04/28/21
Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021GlobeNewsWire • 04/27/21
Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle BiosciencesGlobeNewsWire • 04/27/21
3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19Zacks Investment Research • 04/09/21
Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing LeadersGlobeNewsWire • 03/29/21
Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in JapanGlobeNewsWire • 03/24/21
MYRIAD GENETICS ALERT: Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the FirmBusiness Wire • 03/24/21
Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing ServicesGlobeNewsWire • 03/02/21
Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/21
Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation PlanGlobeNewsWire • 02/23/21
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth InitiativesGlobeNewsWire • 02/18/21
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021GlobeNewsWire • 02/16/21
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics' Prolaris® test to Guide Treatment for Prostate CancerGlobeNewsWire • 02/12/21
Myriad Genetics to Participate in Multiple Upcoming Health and Technology ConferencesGlobeNewsWire • 02/11/21
GeneSight Psychotropic Test's Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood LevelsGlobeNewsWire • 02/08/21